Cover Image
市場調查報告書

屈光異常:主要18個國家的市場預測 (2018∼2028年)

EPIOMIC EPIDEMIOLOGY SERIES: REFRACTIVE ERRORS FORECAST IN 18 MAJOR MARKETS 2018-2028

出版商 Black Swan Analysis 商品編碼 607599
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
屈光異常:主要18個國家的市場預測 (2018∼2028年) EPIOMIC EPIDEMIOLOGY SERIES: REFRACTIVE ERRORS FORECAST IN 18 MAJOR MARKETS 2018-2028
出版日期: 2018年02月01日 內容資訊: 英文 148 Pages
簡介

本報告提供全球主要18個國家的屈光異常的發病情形相關分析,疾病概要和目前的患病人數,各子類型及性別、各年代 (隔5歲)的詳細情況,各地區、各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症 (眼疲勞,頭痛,青光眼,白內障,弱視,屈光不同,糖尿病,動脈性高血壓等),未來趨勢預測 (今後10年份) 的資訊彙整,為您概述為以下內容。

目錄

  • 圖表一覽
  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷方法
  • 各地區/各民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要共生病症/特徵
  • 患者數的測量方法
  • 屈光異常的最大患病人數
    • 遠視
    • 近視
    • 老花眼
  • 屈光異常的特徵
    • 遠視
    • 近視
    • 老花眼
  • 文中的簡稱一覽
  • Black Swan Analysis的其他的出版刊物
    • 報告書、出版刊物
    • 線上流行病學資料庫
    • 線上藥價資料庫
  • 參考文獻
  • 附錄

分析觀察對象國家

  • 美國
  • 加拿大
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 波蘭
  • 荷蘭
  • 土耳其
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 阿根廷
目錄
Product Code: RFER0010218

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Refractive Errors in 18 Major Markets

The main role of the optical components of the eye is focusing rays of light on the retina. Situation in which parallel rays are focused properly is known as emmetropia. Various defects caused by the inability of the eye to converge the refracted rays on the retina are known as refractive errors (ametropias). The report covers the features and epidemiology facts of hyperopia, myopia and presbyopia.

This report provides the current prevalent population for refractive errors across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of refractive errors patients, as well as the main comorbidities of the covered conditions have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of refractive errors include:

  • Eye strain
  • Headaches
  • Glaucoma
  • Cataracts
  • Amblyopia
  • Anisometropia
  • Diabetes mellitus
  • Arterial hypertension

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global refractive errors market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of refractive errors and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the prevalent population of refractive errors patients.
  • Identification of refractive errors patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of refractive errors patients.

Table of Contents

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR REFRACTIVE ERRORS
  • HYPEROPIA
  • MYOPIA
  • PRESBYOPIA
  • FEATURES OF REFRACTIVE ERROR PATIENTS
  • HYPEROPIA
  • MYOPIA
  • PRESBYOBIA
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Types and severity categories of refractive errors
  • Table 2. Prevalence of refractive errors, total (000s)
  • Table 3. Prevalence of refractive errors, males (000s)
  • Table 4. Prevalence of refractive errors, females (000s)
  • Table 5. Prevalence of hyperopia, total (000s)
  • Table 6. Prevalence of hyperopia, males (000s)
  • Table 7. Prevalence of hyperopia, females (000s)
  • Table 8. Prevalence of myopia, total (000s)
  • Table 9. Prevalence of myopia, males (000s)
  • Table 10. Prevalence of myopia, females (000s)
  • Table 11. Prevalence of presbyopia, total (000s)
  • Table 12. Prevalence of presbyopia, males (000s)
  • Table 13. Prevalence of presbyopia, females (000s)
  • Table 14. Patients with hyperopia by severity, total (000s)
  • Table 15. Patients with hyperopia > 3 dioptres, total (000s)
  • Table 16. Patients with anisometropia by difference in dioptres [D], total (000s)
  • Table 17. Patients with hyperopia by smoking status, total (000s)
  • Table 18. Hyperopia patients with diabetes, total (000s)
  • Table 19. Hyperopia patients with glaucoma, total (000s)
  • Table 20. Hyperopia patients with hypertension, total (000s)
  • Table 21. Patients with myopia by severity, total (000s)
  • Table 22. Myopia patients with glaucoma, total (000s)
  • Table 23. Patients with presbyopia by type, total (000s)
  • Table 24. Presbyopia patients earlier diagnosed with hyperopia, total (000s)
  • Table 25. Abbreviations and acronyms used in the report
  • Table 26. USA prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 27. USA prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 28. Canada prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 29. Canada prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 30. France prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 31. France prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 32. Germany prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 33. Germany prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 34. Italy prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 35. Italy prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 36. Spain prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 37. Spain prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 38. UK prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 39. UK prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 40. Poland prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 41. Poland prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 42. Netherlands prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 43. Netherlands prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 44. Turkey prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 45. Turkey prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 46. Japan prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 47. Japan prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 48. China prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 49. China prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 50. South Korea prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 51. South Korea prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 52. India prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 53. India prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 54. Australia prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 55. Australia prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 56. Brazil prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 57. Brazil prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 58. Mexico prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 59. Mexico prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 60. Argentina prevalence of hyperopia by 5-yr age cohort, males (000s)
  • Table 61. Argentina prevalence of hyperopia by 5-yr age cohort, females (000s)
  • Table 62. USA prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 63. USA prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 64. Canada prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 65. Canada prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 66. France prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 67. France prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 68. Germany prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 69. Germany prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 70. Italy prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 71. Italy prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 72. Spain prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 73. Spain prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 74. UK prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 75. UK prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 76. Poland prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 77. Poland prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 78. Netherlands prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 79. Netherlands prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 80. Turkey prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 81. Turkey prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 82. Japan prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 83. Japan prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 84. China prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 85. China prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 86. South Korea prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 87. South Korea prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 88. India prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 89. India prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 90. Australia prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 91. Australia prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 92. Brazil prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 93. Brazil prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 94. Mexico prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 95. Mexico prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 96. Argentina prevalence of myopia by 5-yr age cohort, males (000s)
  • Table 97. Argentina prevalence of myopia by 5-yr age cohort, females (000s)
  • Table 98. USA prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 99. USA prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 100. Canada prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 101. Canada prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 102. France prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 103. France prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 104. Germany prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 105. Germany prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 106. Italy prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 107. Italy prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 108. Spain prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 109. Spain prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 110. UK prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 111. UK prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 112. Poland prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 113. Poland prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 114. Netherlands prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 115. Netherlands prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 116. Turkey prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 117. Turkey prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 118. Japan prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 119. Japan prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 120. China prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 121. China prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 122. South Korea prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 123. South Korea prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 124. India prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 125. India prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 126. Australia prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 127. Australia prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 128. Brazil prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 129. Brazil prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 130. Mexico prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 131. Mexico prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Table 132. Argentina prevalence of presbyopia by 5-yr age cohort, males (000s)
  • Table 133. Argentina prevalence of presbyopia by 5-yr age cohort, females (000s)
  • Figure 1. Differences in the prevalence of hyperopia in the current adult smoking and non-smoking US populations according to 2015 data
  • Figure 2. Differences in the prevalence of myopia in East Asian and Western European countries
Back to Top